A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
110estimated
Sites
39
Countries
Australia, Austria, Canada +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2012-05-22 | actual | When the study began enrolling |
| Primary completion | 2015-03-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2012-05-09 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neoplasms, Hematologic
Intervention
- Drug: 120 mg LY2784544
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants with an Objective Response (Objective Response Rate)
measured Baseline until Disease Progression (PD) or Participant Stops Study (Estimated up to 24 Months)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed